ADMP
Adamis Pharmaceuticals Corp
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
Adamis Pharmaceuticals Corporation is a specialty biopharmaceutical company primarily focused on developing and commercializing products in various therapeutic areas, including allergy, opioid overdose, respiratory and inflammatory disease. The company's SYMJEPI (epinephrine) Injection products are approved by the FDA for use in the emergency treatment of acute allergic reactions, including anaphylaxis. Adamis' naloxone injection product candidate, ZIMHI, for the treatment of opioid overdose is currently under FDA review. Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, influenza, asthma, and COPD. The company's subsidiary, US Compounding Inc., compounds sterile prescription drugs, and certain nonsterile drugs for human and veterinary use by hospitals, clinics, surgery centers, and vet clinics throughout most of the United States. Forward Looking Statements
Market Cap: 156 Million
Primary Exchange: NASDAQ
Website: www.adamispharmaceuticals.com
Shares Outstanding: 149 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.34523486012793
Sector: Manufacturing
Industry: Pharmaceutical Preparation Manufacturing
Ethical Flags
Longest drawdown: 2288 trading days
From: 2013-02-12 To: 2021-09-23
Lowest Point:
Adamis: Share Price Continues To Grind Down To A Fine Discount
via: SeekingAlpha at 2019-06-13 04:24:20:000
Adamis Pharmaceuticals ( ADMP ) is a specialty biopharmaceutical company dedicated to developing and commercializing various therapeutic products. The company's leading product, SYMJEPI, is a pre-filled syringe "PFS" device holding 0.3mg or 0.15mg dosage of epinephrine that has FDA approval fo… read more...
Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval
via: SeekingAlpha at 2019-06-11 07:39:43:000
Based on FDA feedback, Adamis Pharmaceuticals ( ADMP -4.5% ) has removed kalo's EVZIO (naloxone HCl injection) 2 mg auto-injector as the Reference Listed Drug (RLD) in its marketing application seeking approval for its higher dose naloxone injection product for the emergency trea… read more...
Adamis amends U.S. application for higher dose naloxone, hopes for speedy approval
via: SeekingAlpha at 2019-06-11 07:39:43:000
Based on FDA feedback, Adamis Pharmaceuticals ( ADMP -4.5% ) has removed kalo's EVZIO (naloxone HCl injection) 2 mg auto-injector as the Reference Listed Drug (RLD) in its marketing application seeking approval for its higher dose naloxone injection product for the emergency trea… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|---|---|---|---|---|---|
| 2013-12-13 | 17.0 | 1.0 | 17.0 |